Results 181 to 190 of about 2,010,339 (314)

Targeting CBP revers chemoresistance to 5‐FU of CDX2/REG4 double‐positive gastric cancer

Clinical and Translational Medicine
Zhiyuan Fan, Fangyuan Li, Xiao Jiang, Tao Pan, Mingde Zang, Jianfang Li, Beiqin Yu, Qingqing Sang, Wentao Liu, Liping Su, Chen Li, Zhenggang Zhu, Min Yan, Chao Yan, Fei Yuan, Bingya Liu   +15 more
doaj   +1 more source

Disparities in blood cancer survival in the UK 2009-2019: national cohort studies. [PDF]

BJC Rep
Hoang J, Allen J, Capel R, Thomas R, Smits S, Ahmed R, Webb H, Sheikh A, Cox S, Bygrave C, Hippisley-Cox J.   +10 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Syndactyly and Risk of Cancer. [PDF]

Hand (N Y)
Smith KL, Abola MV, Good LM, Liu RW, Shah AS, Trehan SK, Daluiski A.   +6 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

An Analysis of 50 Cases of Salivary Gland Neoplasms: A Single-Institution Experience. [PDF]

Cureus
Kaur K, Singh G, Prinja S, Nibhoria S.
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source

BRAF Mutations in Myeloid Neoplasms: Prevalence, Co-Mutation Landscape, and Clinical Outcomes-A Comprehensive Review. [PDF]

Biomedicines
Mohamed SF, Mohamed A, Mudarres MF, Abdalla AEA, Al-Mashdali AF, Abdulgayoom M, Mesilhy R, Abuasab T, Cherif H, Borthakur G.   +9 more
europepmc   +1 more source

THYMIC NEOPLASMS

Journal of Thoracic Surgery, 1952
E R, FISHER, D, COBURN, D B, EFFLER
openaire   +2 more sources